A 75-Year-Old Woman with Muscle-Invasive Bladder Cancer

Expert oncologist Terence Friedlander, MD, discusses the case of a 75-year-old woman with muscle-invasive bladder cancer and reviews the options for treatment in the adjuvant setting.

EP. 1: Case Presentation: A 75-Year-Old Woman with Muscle-Invasive Bladder Cancer (MIBC)

December 20th 2022

Terence Friedlander, MD, presents the case of a 75-year-old patient with stage IIIA muscle-invasive bladder cancer (MIBC) for review, and explains how patients are risk-stratified.

EP. 2: Eligibility for Cisplatin Therapy in Patients with MIBC

December 20th 2022

Dr Terence Friedlander defines cisplatin eligibility in patients with MIBC and discusses how many patients receive neoadjuvant cisplatin and the treatment approaches if a patient is ineligible.

EP. 3: Available Adjuvant Therapy Options for Patients with Stage II or III MIBC after Cystectomy

December 20th 2022

Terence Friedlander, MD, reviews the available adjuvant therapy options for patients with stage II or III MIBC who previously underwent bladder removal surgery.

EP. 4: Adjuvant Nivolumab Therapy for MIBC: Safety and Efficacy Data from CheckMate 274

December 20th 2022

Dr Terence Friedlander explains safety and efficacy data from the CheckMate 247 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC.

EP. 5: CheckMate 274: Data Updates in MIBC from GU ASCO, ASCO, and ESMO 2022

December 20th 2022

Terence Friedlander, MD, continues his discussion of the CheckMate 247 trial by highlighting important updates from recent conferences on adjuvant nivolumab therapy in patients with MIBC.

EP. 6: Factors for Consideration when Choosing an Adjuvant Therapy Regimen for Patients with MIBC

December 20th 2022

Dr Terence Friedlander explains which adjuvant therapy he would have recommended for the patient with MIBC from the presented case.

EP. 7: Critical Unmet Needs for Patients with MIBC

December 20th 2022

Terence Friedlander, MD, summarizes the remaining unmet needs for patients with MIBC.

EP. 8: The Future of Neoadjuvant Immunotherapy in MIBC

December 20th 2022

Dr Terence Friedlander closes his discussion by highlighting ongoing clinicals in neoadjuvant MIBC treatment that excite him and speculates on how he would use immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant setting.